Shukra Pharmaceuticals Ltd operates in the B2B generics and specialty pharma space with potential exposure to API manufacturing. Key business lines remain unspecified due to limited disclosed data, but thematic links suggest reliance on contract manufacturing or niche therapeutic areas. Growth depends on industry tailwinds for generic drug demand and API outsourcing, though absence of concrete guidance, margin visibility, or pipeline details hinders clarity. Over 2-3 years, the business could benefit from pharma sector cost pressures driving contract manufacturing activity, but execution risks center on scaling capacity or maintaining margins without stated operational milestones. Limited data on order flow, client concentration, or margin trends restricts confidence in near-term trajectory.
companyname: Shukra Pharmaceuticals Limited ticker: SHUKRAPHAR sector: Pharmaceuticals Shukra Pharmaceuticals Limited is a Gujarat-based manufacturer and exporter of finished-dose pharmaceutical products. Incorporated in 1993 and listed on the BSE under scrip 524632, it runs a WHO-GMP certified formulation plant on a 10-acre campus at Rakanpur in Gandhinagar district, with its registered office in Ahmedabad. The company had 115 permanent employees as of 31 March 2025 and operates as a standalon...
Read the full report →Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Shukra Pharmaceuticals Limited and 4,900+ companies.
5-day free pass. No card required.